ライフサイエンスコーパス: cytotoxic T-cell

1 e clearance of the treated cells mediated by cytotoxic T cells.

2 nd increasing the number of tumor-associated cytotoxic T cells.

3 lectively and its effects on intraepithelial cytotoxic T cells.

4 of TNFalpha and YAP1 and low infiltration of cytotoxic T cells.

5 recognition by the T cell receptor (TCR) of cytotoxic T cells.

6 tly, susceptibility to lysis by PR1-specific cytotoxic T cells.

7 reduced expression of cytokines produced by cytotoxic T cells.

8 and targeted for elimination by Ag-specific cytotoxic T cells.

9 reduced signature of markers characterizing cytotoxic T cells.

10 and were infiltrated with mutation-specific cytotoxic T cells.

11 lated membrane attack complex, exotoxins, or cytotoxic T cells.

12 d promote progression through suppression of cytotoxic T cells.

13 atively activated intestinal intraepithelial cytotoxic T cells.

14 rapy promotes the killing of cancer cells by cytotoxic T cells.

15 filtrating CD4 helper T cells and CD8 memory cytotoxic T cells.

16 HLA-B27 of presenting antigenic peptides to cytotoxic T cells.

17 fect was associated with a reduced influx of cytotoxic T cells.

18 erized by HA-specific CD4 T helper 1 and CD8 cytotoxic T cells.

19 ing their interaction with SLAMF4-expressing cytotoxic T cells.

20 cells, plasma B cells, and memory helper and cytotoxic T cells.

21 s I loading and cell surface presentation to cytotoxic T cells.

22 modulate immune recognition by NK cells and cytotoxic T cells.

23 euronal death in the presence of appropriate cytotoxic T cells.

24 class I proteins that might be recognized by cytotoxic T cells.

25 xicity and long-term persistence provided by cytotoxic T cells.

26 ules display peptides at the cell surface to cytotoxic T cells.

27 al clearance is mediated by the functions of cytotoxic T cells.

28 electively bind peptides for presentation to cytotoxic T cells.

29 dedifferentiated cell state upon exposure to cytotoxic T cells.

30 ctivity of immune cells, including decreased cytotoxic T cells.

31 with blood vessel dysfunction and a lack of cytotoxic T cells.

32 r growth in mice in a manner that depends on cytotoxic T cells.

33 romoting robust intratumoral infiltration of cytotoxic T cells.

34 SOX4 expression and sensitizes TNBC cells to cytotoxic T cells.

35 ty to recognition and elimination by cognate cytotoxic T cells.

36 cally activated inflammatory macrophages and cytotoxic T cells.

37 ol for HLA presentation of HIV-1 epitopes to cytotoxic T cells.

38 exosomes in facilitating the suppression of cytotoxic T cells.

39 rget MHC I molecules to avoid recognition by cytotoxic T cells.

40 ene silencing and promote tumor clearance by cytotoxic T cells.

41 such as immune-stimulatory myeloid cells and cytotoxic T cells.

42 e highest CD68 expression and associate with cytotoxic T-cells.

43 mumab induced robust increases in helper and cytotoxic T-cell absolute counts.

44 Helper and cytotoxic T cells accomplish focused secretion through t

45 Treatment with tamoxifen increases liver cytotoxic T cell accumulation and reduces colon cancer L

46 ting these pathways can indirectly stimulate cytotoxic T cell activation and recruitment, and synergi

47 h defective MHC class I expression, impaired cytotoxic T cell activation, and poor patient prognosis.

48 es increased type I interferon signaling and cytotoxic T-cell activation.

49 This often relies on repurposing cytotoxic T cell activity through modified T cell recept

50 was normal, in vitro-generated EBV-specific cytotoxic T cell activity was reduced because of CD70 de

51 CTLA4), CD80-expressing tSCs directly dampen cytotoxic T cell activity.

52 hese classes of therapeutics is dependent on cytotoxic T-cell activity and is associated with a reduc

53 generate neo-antigenic epitopes that elicit cytotoxic T-cell activity and subsequent pressure to sel

54 unction and is a potential target to improve cytotoxic T-cell activity.Grail is an E3 ubiquitin ligas

55 Th and cytotoxic T cells also contained IL-26.

56 nse, interferon-gamma and rejection-induced, cytotoxic T cell and constitutive macrophage-associated

57 pecificity as HLA-A*0201/IMP(58-66)-specific cytotoxic T cells and bound neither to HLA-A*0201 nor th

58 ne response by providing help to B cells and cytotoxic T cells and by releasing different types of cy

59 y collagen were less efficient at attracting cytotoxic T cells and capable of inhibiting T cell proli

60 mesothelioma through systemic activation of cytotoxic T cells and enhanced production of IFN-gamma a

61 ed numbers of bone marrow-infiltrating OX40+ cytotoxic T cells and helper T cells, as well as decreas

62 recruit PA-CXCR4-expressing tumor-targeting cytotoxic T cells and improved the efficacy of adoptive

63 d that AC-NPs induced an expansion of CD8(+) cytotoxic T cells and increased both CD4(+)T/Treg and CD

64 ation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression.

65 tumors had significantly few CD8(+)/PD-1(+) cytotoxic T cells and more CD25(+)/FOXP3(+) regulatory T

66 ficiencies in trafficking and/or function of cytotoxic T cells and natural killer (NK) cells.

67 The results showed increased activity of cytotoxic T cells and natural killer cells in BKVN and v

68 More importantly, PMVDS stimulated both cytotoxic T cells and natural killer cells of cell-media

69 s, granzyme B production by cytotoxic cells (cytotoxic T cells and natural killer cells), and interle

70 nes, and adoptive transfer of tumor-specific cytotoxic T cells and natural killer cells, have been cl

71 imicrobial peptide (AMP) that is produced by cytotoxic T cells and natural killer cells.

72 "exercise-induced leukocytosis"), especially cytotoxic T cells and natural killer cells.

73 cal proteins required for normal function of cytotoxic T cells and NK cells) or secondary (resulting

74 sponse in advanced thyroid cancers linked to cytotoxic T cells and NK cells.

75 tes the proliferation and differentiation of cytotoxic T cells and NK cells.

76 ll lines to differentiation antigen-specific cytotoxic T cells and observe strong enrichment of a pre

77 of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells.

78 by an increase in stromal CD8(+)IFNgamma(+) cytotoxic T cells and significant attenuation of tumor c

79 Human GIFT4-licensed B cells primed cytotoxic T cells and specifically killed melanoma cells

80 tribute to the activation of intraepithelial cytotoxic T cells and the development of villous atrophy

81 ate a bispecific antibody designed to engage cytotoxic T cells and trigger tumor cell killing.

82 MARCO-expressing TAMs blocked cytotoxic T-cell and NK-cell activation, inhibiting thei

83 ycle progression, suppressed infiltration of cytotoxic T cells, and accelerated SCLC.

84 enal parenchyma by activated macrophages and cytotoxic T cells, and acute tubular injury.

85 Cytotoxic T cells are essential mediators of protective

86 Cytotoxic T cells are of central importance in the immun

87 Although functionally competent cytotoxic, T cells are frequently observed in malignant

88 e cell types, while CD8(+) T cells (known as cytotoxic T cells) are major cells that provide immunity

89 hological features (invasion of myofibres by cytotoxic T cells) are unique among muscle diseases.

90 ls of seven activation markers on helper and cytotoxic T cells as well as the percentage of CD4(+) CD

91 granzyme B, a downstream effector of tumoral cytotoxic T cells, as an early biomarker for tumors resp

92 and progenitors in the presence of activated cytotoxic T cells, as occurs in human BM failure.

93 2-low asthma exhibit an airway deficiency in cytotoxic T cells associated with obesity-driven inflamm

94 Immunomodulatory antibodies directed against cytotoxic T cell-associated antigen 4 (CTLA-4/CD152) and

95 g, cytolytic granule composition, type 1 CD8 cytotoxic T cell-associated effector molecules granzyme

96 umoral infiltration and activation of CD8(+) cytotoxic T cells, attenuated growth of pancreatic neopl

97 ) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemok

98 signaling provides costimulatory signals to cytotoxic T cells but also increases the frequency of re

99 NO by inflammatory DCs and the activation of cytotoxic T cells by splenic CD8alpha(+) DCs.

100 nd in particular T helper (Th) 1, Th17, CD8+ cytotoxic T cells, CD19+ B cells and CD56+ natural kille

101 11b+), increased dendritic cells (CD86+) and cytotoxic T cells (CD8+) in the p65 knockout (KO) mice.

102 Cytotoxic T cells clear virus-infected host cells and co

103 Targeting highly differentiated cytotoxic T cells could be a favourable approach to trea

104 In addition, the proportion of NK and cytotoxic T cell (CTL) expressing perforin and granzyme

105 PCs) within tumors typically do not maintain cytotoxic T cell (CTL) function, despite engaging them.

106 ERK) antigen, the action of antigen-specific cytotoxic T cell (CTL) in vivo results in the emergence

107 hetic subunit vaccines need to induce CD8(+) cytotoxic T cell (CTL) responses for effective vaccinati

108 + T cells that persists despite HIV-specific cytotoxic T cell (CTL) responses.

109 profound remodeling of the TME and unleashed cytotoxic T cell (CTL)-mediated tumor eradication.

110 ontrol of hepatitis C virus (HCV) infection, cytotoxic T cells (CTL) are pivotal, but persistence of

111 iled map of IL-2 protein phosphorylations in cytotoxic T cells (CTL).

112 ells (DCs) are required for the induction of cytotoxic T cells (CTL).

113 get N for cytosolic degradation and generate cytotoxic T cells (CTLs) against N peptide.

114 tory signaling that enhances the activity of cytotoxic T cells (CTLs) could identify potential target

115 nhanced the frequency of T-helper/memory and cytotoxic T cells (CTLs) in peripheral blood mononuclear

116 se Peripheral blood-derived antigen-specific cytotoxic T cells (CTLs) provide a readily available sou

117 Cancer immunotherapy in which cytotoxic T cells (CTLs) target tumor-specific antigens

118 (n = 4), naive (n = 3) and activated (n = 3) cytotoxic T cells (CTLs), and natural killer (NK) (n = 4

119 of tumour antigens that can activate CD8(+) cytotoxic T cells (CTLs), but the microenvironment of es

120 rectly prime or cross-prime MHC I-restricted cytotoxic T cells (CTLs).

121 First, ovalbumin (OVA) antigen-specific cytotoxic T-cells (CTLs) were incubated with N-azidoacet

122 esults suggest that broad, highly functional cytotoxic T cells (cytotoxic T lymphocytes [CTLs]) again

123 -PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism.

124 ned treatment limited tumor progression in a cytotoxic T-cell-dependent manner, as depletion of CD8(+

125 aves basement membrane proteins and promotes cytotoxic T cell diapedesis into inflamed tissue.

126 Thus, the cytokine acts to control cytotoxic T cell differentiation in lymphoid and periphe

127 Cytotoxic T cell differentiation is guided by epigenome

128 ction of Runx3, a nuclear factor crucial for cytotoxic T cell differentiation.

129 We show that cytotoxic T cells directed against the N-terminal peptid

130 and over one year show little indication of cytotoxic T cell-driven immune selections.

131 nt cohorts revealed strong associations with cytotoxic T-cell dysfunction and exclusion, respectively

132 led more efficient expansion of E75-specific cytotoxic T cells (E75-CTL).

133 L) sensitized cells to lysis by EBV-specific cytotoxic T cells (EBV-CTLs).

134 T cell-specific coreceptor CD4 in helper and cytotoxic T cells exemplifies this process, with enhance

135 ful platform for generating large numbers of cytotoxic T cells for cancer immunotherapy.

136 tractive method to generate large numbers of cytotoxic T cells for immunotherapy of cancer and viral

137 actions were significantly lower, while CD8+ cytotoxic T cell fractions were significantly higher, co

138 effective tools to isolate rare high-avidity cytotoxic T cells from patients for use in adoptive ther

139 Intraepithelial cytotoxic T cells from potential celiac disease patients

140 Intraepithelial cytotoxic T cells from relatives of patients with celiac

141 viral interference with the ultimate step in cytotoxic T cell function, the death of infected cells.

142 s study, we evaluated the role of mir-155 in cytotoxic T cell function.

143 e cells can similarly modulate the degree of cytotoxic T-cell function and activity in the tumour mic

144 creased expression of negative regulators of cytotoxic T-cell function.

145 glycosylation of alpha dystroglycan with the cytotoxic T cell glycan and increases the overexpression

146 glycosylation of alpha dystroglycan with the cytotoxic T cell glycan or increased expression of dystr

147 first time that resistance of kidney TEC to cytotoxic T-cell granzyme B-induced death in vitro and i

148 uccess; the use of autologous virus-specific cytotoxic T cells has proved effective as well.

149 ture types), and killer cells (consisting of cytotoxic T cells, helper T cells, effector B cells, and

150 gocytic engulfment and force dynamics in the cytotoxic T-cell immunological synapse.

151 This invasive capability of CD8(+) cytotoxic T cells in collaboration with phagocytes appea

152 tudy supports a role for both regulatory and cytotoxic T cells in determining cancer risk among healt

153 egulatory T cells in addition to suppressing cytotoxic T cells in different tumor models.

154 nalyzed epithelial cells and intraepithelial cytotoxic T cells in family members of patients with cel

155 D-1 and interleukin-10 (IL-10) expression by cytotoxic T cells in H5N1 (2:6)-infected mice, suggestin

156 d tissue-restricted, metabolically repressed cytotoxic T cells in human colorectal carcinoma.

157 nsion of circulating plasmablasts and CD4(+) cytotoxic T cells in patients with IgG(4)-related diseas

158 Spatial distribution of cytotoxic T cells in proximity to cancer cells correlate

159 ty to activate both CD4(+) helper and CD8(+) cytotoxic T cells in response to necrotic cells and may

160 d enhanced lysis of melanoma cells by CD8(+) cytotoxic T cells in vitro.

161 iferation and activation of insulin-reactive cytotoxic T cells in vitro.

162 te an important role for TNF-alpha-producing cytotoxic T-cells in mediating the anti-cancer effects o

163 ectively; (3) increased CD4+ helper and CD8+ cytotoxic T-cells in the spleen; and (4) profound spleni

164 s formed in WNT5A knockout mice had elevated cytotoxic T cells, increased M1 macrophages, and decreas

165 Cytotoxic T cells infiltrating tumors are thought to uti

166 virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy o

167 ress, antiviral pathways, IFN signaling, and cytotoxic T cell infiltration in human cancers, while a

168 led gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-gamma (IFN-

169 in EOC tissue and inversely correlated with cytotoxic T cell infiltration, suggesting that HE4 may c

170 with high levels of fibrosis and poor CD8(+) cytotoxic T cell infiltration.

171 40 pathway in the mouse cancer model boosted cytotoxic T cell infiltration.

172 SUNb-PM not only increased cytotoxic T-cell infiltration and decreased the number a

173 d-derived suppressor cells and inhibition of cytotoxic T-cell infiltration.

174 on of Th-1 chemokines, migration of Th-1 and cytotoxic T cells into the tumor, and activation of immu

175 o an immunoresponsive one by recruiting CD8+ cytotoxic T cells into tumor beds.

176 tion of cross-protective immunoglobulins and cytotoxic T cells is a possible mechanism.

177 Restoring the levels and activity of cytotoxic T cells is a promising anticancer strategy; bu

178 ction in TAMs the percentage of infiltrating cytotoxic T cells is increased, indicating a change in t

179 IL-33, required for viral clearance by cytotoxic T cells, is generally expressed in vascular en

180 in blood cell composition (notably exhausted cytotoxic T cells), it is less clear what explains the o

181 CD8(+) cytotoxic T cells kill target cells through direct cell-

182 ion, and also in cross-priming and licensing cytotoxic T cell killers in vivo.

183 dy, mimicking one of the major mechanisms of cytotoxic T cell killing, inhibits B cell receptor-media

184 nergizes with CBI to expand and reinvigorate cytotoxic T cells, leading to superb anticancer efficacy

185 elper T cells TH1 and TH2 serum antibody and cytotoxic T-cell levels compared to bolus controls.

186 d activated T cells, naive helper T (Th) and cytotoxic T cells, loss of CD56bright regulatory NK cell

187 We reasoned that concurrent cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) checkpoin

188 patients in our analysis, 32 resumed an anti-cytotoxic T-cell lymphocyte-4 (CTLA-4) agent, and 135 an

189 rammed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyte-associated 4 antibody) in pa

190 expression by T cells, and downregulation of cytotoxic T cell lytic potential.

191 8+ lymphocyte infiltration and expression of cytotoxic T-cell markers and effector cytokines, similar

192 o investigate the association of CPS-induced cytotoxic T-cell markers with protection.

193 ockade that can be mediated by activation of cytotoxic T cells may be overcome in some tumor microenv

194 esented by Li et al shows that memory CD8(+) cytotoxic T cells mediate fibrosis via the secretion of

195 mine the mechanisms by which intraepithelial cytotoxic T cells mediate tissue destruction in celiac d

196 INCR1 knockdown sensitizes tumor cells to cytotoxic T cell-mediated killing, improving CAR T cell

197 significant enhancement of Th1-mediated and cytotoxic T-cell-mediated antitumor immunity.

198 Ultimately, these events promote cytotoxic T-cell-mediated clearance of tumour cells, whi

199 BNZ-2 might be used to prevent cytotoxic T-cell-mediated tissue damage in complex immun

200 e tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targ

201 nce of local immune suppression, transferred cytotoxic T cells more effectively controlled tumors in

202 cells, we were able to stimulate peripheral cytotoxic T cells obtained from colorectal cancer patien

203 Effective immune surveillance by CD8(+) cytotoxic T cells of intracellular microbes and cancer d

204 a is a chronic clonal lymphoproliferation of cytotoxic T cells often associated with autoimmune disea

205 Monocyte, natural killer (NK) cell, and cytotoxic T-cell p11 levels were positively associated w

206 Cytotoxic T cells play a key role in adaptive immunity b

207 immunological control, primarily mediated by cytotoxic T cells, plays a critical role in preventing C

208 howed the highest CLA(+)/CLA(-) T(H)1/type 1 cytotoxic T-cell polarization, with parallel T(H)2/T(H)9

209 During the medication, the cytotoxic T cell population increased while the populati

210 to brain peptides in circulating B cell and cytotoxic T cell populations.

211 or (89)Zr-immuno-PET detection of helper and cytotoxic T cell populations.

212 associated with infiltrating regulatory and cytotoxic T-cell populations, suggesting distinct immuno

213 a and rejection induced (GRIT), quantitative cytotoxic T-cell (QCAT), quantitative constitutive and a

214 LA-B from the cell surface in order to evade cytotoxic-T-cell recognition, while leaving HLA-C and HL

215 ts and were extensively infiltrated by mouse cytotoxic T cells, reflecting a vigorous host anti-tumor

216 ENCA mitochondrial lysate vaccine elicited a cytotoxic T cell response in vivo and conferred durable

217 However, the cytotoxic T cell response may also be required after cur

218 rotection against T. parva involves a CD8(+) cytotoxic T cell response to parasite-infected cells.

219 T cell clonal expansions and diminishes the cytotoxic T cell response to subsequent infections, lead

220 oantigen that can specifically elicit a host cytotoxic T cell response.

221 mors by generating a systemic tumor-specific cytotoxic T cell response.

222 s) and thus stimulate a tumor-specific, CD8+ cytotoxic T cell response.

223 responses, with a weaker than desired CD8(+) cytotoxic T cell response.

224 onal signature that correlated with enhanced cytotoxic T-cell response in human solid tumors.

225 oparticle, PC7A NP, which generates a strong cytotoxic T-cell response with low systemic cytokine exp

226 es and high viremia, Cl13 generated a robust cytotoxic T-cell response, resulting in thrombocytopenia

227 potentially be used in vaccines to increase cytotoxic T cell responses against Ags that are targeted

228 Tem1-TT vaccination also elicited CD8+ cytotoxic T cell responses against murine tumor-specific

229 t MTM, depletion restores tumor-infiltrating cytotoxic T cell responses and suppresses tumor growth.

230 lated cancers are usually designed to elicit cytotoxic T cell responses by targeting the HPV-16 E7 on

231 rsistent-latent virus that elicits different cytotoxic T cell responses characterized as acute resolv

232 played by these alleles and drive helper and cytotoxic T cell responses in patients with Parkinson's

233 booster vaccination significantly increased cytotoxic T cell responses to subdominant highly conserv

234 Ex vivo examination of cytotoxic T cell responses to the entire HIV-1 proteome

235 ellular innate immune responses and adaptive cytotoxic T cell responses.

236 ene fusion-derived neoantigens that generate cytotoxic T cell responses.

237 ain source of alloantigen that drives CD8(+) cytotoxic T cell responses.

238 tial role in the elicitation of antibody and cytotoxic T cell responses.

239 geting immunomodulatory receptors to promote cytotoxic T cell responses.

240 class I expression and its ability to elicit cytotoxic T cell responses.

241 tumor specific and have been shown to elicit cytotoxic T cell responses.

242 ll responses and provide help for B cell and cytotoxic T cell responses.

243 hey induce strong protective and therapeutic cytotoxic T cell responses.

244 integral to human T helper type 1 (Th1) and cytotoxic T cell responses.

245 conditions of tumour cells induced systemic cytotoxic T-cell responses and immunological memory asso

246 pamycin completely abolished vaccine-induced cytotoxic T-cell responses and therapeutic activity.

247 th the ability to stimulate antigen-specific cytotoxic T-cell responses during tumor development.

248 s II region only, implying the importance of cytotoxic T-cell responses for the former and CD4(+) T-c

249 ized by a macrophage-mediated improvement of cytotoxic T-cell responses through the induction of cyto

250 Long-lived cytotoxic T-cell responses were detected against peptide

251 Functional cytotoxic T-cell responses, including responses to one m

252 nsfected and endogenous antigens and enhance cytotoxic T-cell responses, indicating that these enzyme

253 genes associated with acute inflammatory or cytotoxic T-cell responses.

254 ar focus on the development of antibacterial cytotoxic T-cell responses.

255 p shape the antigenic peptide repertoire and cytotoxic T-cell responses.

256 s to cross-present antigens and to stimulate cytotoxic T-cell responses.

257 ell evaluated for their potential effects on cytotoxic T-cell responses.

258 y, with well-established roles in B-cell and cytotoxic T-cell responses.

259 oteolysis promoted early clonal expansion of cytotoxic T cells resulting in an 8-fold increase over T

260 sequencing studies; the presence of a marked cytotoxic T cell signature in gene expression studies; a

261 with high antigen presentation machinery and cytotoxic T cell signature scores are found to have a pr

262 developed this molecular strategy to render cytotoxic T cells specific for fungi.

263 surements included total T cells, helper and cytotoxic T-cell subsets, naive and memory phenotype of

264 Cytotoxic T cells substantially contribute to the contro

265 sociated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR c

266 ing cells increased over time exclusively on cytotoxic T cells, T-helper cells, and regulatory T cell

267 Tumor-associated antigen cytotoxic T cells (TAA-Ts) represent a new, potentially

268 Here we identified a specialized group of cytotoxic T cells (TC cells) that expressed the chemokin

269 Cytotoxic T cells (Tc) use perforin and granzyme B (gzmB

270 ILCs (ILC1 and natural killer cells), CD8(+) cytotoxic T cells (TC1), and CD4(+) TH1 cells, which pro

271 hese cells, which we have called 'follicular cytotoxic T cells' (TFC cells), required the transcripti

272 s) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC

273 b responses against the sporozoite stage and cytotoxic T cells that eliminate parasite-infected hepat

274 eventually, the activation of tumor-specific cytotoxic T cells, their recruitment into the tumor site

275 apture them and induce tolerance of specific cytotoxic T cells through unknown mechanisms.

276 lls and tumor-associated antigens to recruit cytotoxic T cells to cancer cells, are a promising new a

277 The resulting alphaCLL1-alphaCD3 recruits cytotoxic T cells to CLL1 positive cells, and demonstrat

278 important for adoptively transferred CD8(+) cytotoxic T cells to destroy tumors.

279 a host innate immune system and reactivates cytotoxic T cells to elicit durable response in some can

280 ically programmed biAbs aimed at redirecting cytotoxic T cells to eliminate cancer cells.

281 h epithelial stress to allow intraepithelial cytotoxic T cells to kill epithelial cells and induce vi

282 Empowering the ability of cytotoxic T cells to kill tumor cells or the reframing o

283 olecules are designed to engage and activate cytotoxic T cells to kill tumor cells.

284 unotherapies act by enhancing the ability of cytotoxic T cells to kill tumor cells.

285 A failure of cytotoxic T cells to limit or contract inflammatory resp

286 -DQ8 have a crucial role in the licensing of cytotoxic T cells to mediate intestinal epithelial cell

287 reviously unappreciated capability of CD8(+) cytotoxic T cells to penetrate into a large target, T. g

288 represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing targe

289 at can be effectively challenged by adoptive cytotoxic T cell transfer (ACT)-based immunotherapy.

290 ive transfer of donor-derived virus-specific cytotoxic T cells (VSTs) is a strategy to rapidly restor

291 ive transfer of donor-derived viral-specific cytotoxic T-cells (VSTs) is an effective treatment for c

292 VZV-specific cytotoxic T cell (VZV-CTL) and T follicular helper respo

293 Strikingly, cytotoxic T cells were generated against 37 out of 50 pe

294 Intraepithelial cytotoxic T cells were isolated and levels of inhibitory

295 CD8+ CD57+ cytotoxic T cells were persistently increased after ther

296 macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neoplastic and

297 Furthermore, activation of cytotoxic T cells with combination therapy mediated the

298 Activation of intraepithelial cytotoxic T cells with IL15 or IL21 induced separate sig

299 izes MDSCs and triggers the rapid accrual of cytotoxic T cells, with consequent tumor clearance poten

300 umor immunity by directly stimulating CD8(+) cytotoxic T cells, with the potential to increase curati